NO20084857L - HPV-16-basert papillomavirus vaksine - Google Patents

HPV-16-basert papillomavirus vaksine

Info

Publication number
NO20084857L
NO20084857L NO20084857A NO20084857A NO20084857L NO 20084857 L NO20084857 L NO 20084857L NO 20084857 A NO20084857 A NO 20084857A NO 20084857 A NO20084857 A NO 20084857A NO 20084857 L NO20084857 L NO 20084857L
Authority
NO
Norway
Prior art keywords
hpv
preventing
treating
papillomavirus vaccine
papillomavirus
Prior art date
Application number
NO20084857A
Other languages
English (en)
Norwegian (no)
Inventor
Ronald Rooke
Stephane Paul
Original Assignee
Transgene Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Transgene Sa filed Critical Transgene Sa
Publication of NO20084857L publication Critical patent/NO20084857L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/01—DNA viruses
    • C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/20011—Papillomaviridae
    • C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/24011—Poxviridae
    • C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
    • C12N2710/24141—Use of virus, viral particle or viral elements as a vector
    • C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Genetics & Genomics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
NO20084857A 2006-04-21 2008-11-18 HPV-16-basert papillomavirus vaksine NO20084857L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP06360014 2006-04-21
PCT/EP2007/003368 WO2007121895A2 (fr) 2006-04-21 2007-04-17 Vaccin contre le papillomavirus

Publications (1)

Publication Number Publication Date
NO20084857L true NO20084857L (no) 2008-11-18

Family

ID=38362856

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20084857A NO20084857L (no) 2006-04-21 2008-11-18 HPV-16-basert papillomavirus vaksine

Country Status (13)

Country Link
US (1) US20100061957A1 (fr)
EP (1) EP2013230A2 (fr)
JP (1) JP2009534332A (fr)
KR (1) KR20090005011A (fr)
CN (1) CN101426811A (fr)
AU (1) AU2007241406A1 (fr)
BR (1) BRPI0710238A2 (fr)
CA (1) CA2649392A1 (fr)
IL (1) IL193661A0 (fr)
MX (1) MX2008013488A (fr)
NO (1) NO20084857L (fr)
RU (1) RU2008145712A (fr)
WO (1) WO2007121895A2 (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8877206B2 (en) 2007-03-22 2014-11-04 Pds Biotechnology Corporation Stimulation of an immune response by cationic lipids
US8926961B2 (en) * 2007-10-03 2015-01-06 Board Of Trustees Of The University Of Arkansas HPV E6 protein T cell epitopes and uses thereof
EP2276495B1 (fr) 2008-04-17 2018-11-21 PDS Biotechnology Corporation Stimulation de réponse immunitaire par des énantiomères de lipides cationiques
EP2239330A1 (fr) * 2009-04-07 2010-10-13 Institut Pasteur Génération, régénération et protection de neurones
AU2011279365A1 (en) * 2010-07-15 2013-03-07 British Columbia Cancer Agency Branch Human papillomavirus E7 antigen compositions and uses thereof
CN102343103B (zh) * 2011-07-26 2016-04-27 马丁 人乳头状瘤病毒16型三肽疫苗的筛选和验证及持续表达hpv16 e5, e6, e7的肿瘤动物模型的构建
EP2601968A1 (fr) * 2011-12-06 2013-06-12 Deutsches Krebsforschungszentrum Acides polynucléiques dérivés du VPH pour thérapie
CA2876656C (fr) 2012-06-15 2023-09-26 Pds Biotechnology Corporation Compositions de vaccins comportant des lipides cationiques et leurs procedes d'utilisation
CN113144188A (zh) 2012-09-21 2021-07-23 Pds生物科技公司 改进的疫苗组合物和使用方法
US9000736B2 (en) 2013-05-03 2015-04-07 Cooper Technologies Company Power factor correction algorithm for arbitrary input waveform
US9190901B2 (en) 2013-05-03 2015-11-17 Cooper Technologies Company Bridgeless boost power factor correction circuit for constant current input
US9214855B2 (en) 2013-05-03 2015-12-15 Cooper Technologies Company Active power factor correction circuit for a constant current power converter
US9548794B2 (en) 2013-05-03 2017-01-17 Cooper Technologies Company Power factor correction for constant current input with power line communication
CA3005251A1 (fr) 2015-11-13 2017-05-18 Pds Biotechnology Corporation Lipides en tant que vecteurs synthetiques pour ameliorer le traitement et la presentation de l'antigene ex-vivo en therapie cellulaire dendritique
JP2019517522A (ja) * 2016-06-03 2019-06-24 エトゥビクス コーポレーション ヒトパピローマウイルス（ｈｐｖ）関連疾患の処置のための組成物及び方法
EP3522908A4 (fr) 2016-10-05 2020-06-24 PDS Biotechnology Corporation Nouveaux vaccins à lymphocytes t non restreints à des hla de hpv16, compositions et procédés d'utilisation associés
WO2019113200A1 (fr) 2017-12-05 2019-06-13 Pds Biotechnology Corporation Procédés et compositions comprenant des lipides cationiques pour stimuler des gènes d'interféron de type 1
WO2020117715A1 (fr) 2018-12-03 2020-06-11 Board Of Regents, The University Of Texas System Analogues d'oligo-benzamide et leur utilisation dans le traitement du cancer

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AUPN015794A0 (en) * 1994-12-20 1995-01-19 Csl Limited Variants of human papilloma virus antigens
FR2766091A1 (fr) * 1997-07-18 1999-01-22 Transgene Sa Composition antitumorale a base de polypeptide immunogene de localisation cellulaire modifiee
WO2002077012A2 (fr) * 2001-03-23 2002-10-03 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Peptides immunoreactifs du papillomavirus humain
AU2003284239B2 (en) * 2002-10-21 2008-08-21 Eisai Inc. Compositions and methods for treating human papillomavirus-mediated disease

Also Published As

Publication number Publication date
KR20090005011A (ko) 2009-01-12
CA2649392A1 (fr) 2007-11-01
WO2007121895A3 (fr) 2008-03-20
JP2009534332A (ja) 2009-09-24
IL193661A0 (en) 2011-08-01
AU2007241406A1 (en) 2007-11-01
US20100061957A1 (en) 2010-03-11
EP2013230A2 (fr) 2009-01-14
WO2007121895A2 (fr) 2007-11-01
RU2008145712A (ru) 2010-05-27
BRPI0710238A2 (pt) 2011-08-09
CN101426811A (zh) 2009-05-06
MX2008013488A (es) 2008-10-30

Similar Documents

Publication Publication Date Title
NO20084857L (no) HPV-16-basert papillomavirus vaksine
WO2007121894A3 (fr) Vaccin contre le papillomavirus à base de hpv-18
NO20092360L (no) Nye antiproliferasjonsantistoffer
NO20080745L (no) Nye peptider for anvendelse i behandling av fedme
BR112012011100A2 (pt) compostos inibidores do vírus da hepatite, composição e uso dos mesmos
EP2336174B8 (fr) Anticorps monoclonaux humains contre les virus Hendra et Nipah
BRPI0511078A (pt) compostos de pirimidinona cìclicos, composição compreendendo os mesmos, método de inibição e uso
ATE503769T1 (de) Antikörper gegen das humane cytomegalie-virus (hcmv)
MX345700B (es) Proteinas f del vrs modificadas y metodos de uso de las mismas.
ATE449097T1 (de) Pyridoä2,3-düpyrimidin-2,4-diamin-verbindungen als ptpib-hemmer
NO20052071L (no) Bezofuranforbindelser, preparater og metoder for behandling og forebygging av hepatitt C virale infeksjoner og relaterte sykdommer.
NO20084396L (no) Kombinasjonsterapi
UA98658C2 (uk) Циклічні депсипептиди
WO2006075245A3 (fr) Systemes, methodes et compositions pour la detection de papillomavirus humain dans des echantillons biologiques
MX2011007692A (es) Vacunas mejoradas para el virus del papiloma humano y procedimientos para su utilizacion.
NO20081014L (no) Sammensetninger
UA96279C2 (ru) Изолированное антитело или его фрагмент, способное к связыванию с человеческим nogo
ECSP055869A (es) Vacuna hpv-16 y -18 l1 vlp
IL176522A0 (en) Universal amplification of fragmented rna
ATE449612T1 (de) Zusammensetzung zur impfung
BRPI0706871A2 (pt) uso de um extrato de sambucus nigra l., método de tratamento de uma infecção viral de influenza e método de inibição da infecção viral de influenza
NO20070980L (no) Selekterte kondenserte heterocykler og anvendelser derav
NO20080650L (no) Forbindelser omfattende DMXAA for behandling av kreft
EA201000392A1 (ru) Соединение, представляющее собой ингибитор гликогенфосфорилазы, и его фармацевтическая композиция
WO2009120022A3 (fr) Immunopeptide, composition pour la prophylaxie ou le traitement d'états pathologiques médicaux liés au hpv comprenant l'immunopeptide

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application